- The TRIM (Tripartite Motif) family is one of the largest and most functionally diverse groups of single‑chain RING finger ubiquitin ligases in mammals. With more than 70 members identified in humans, TRIM proteins regulate a wide spectrum of biological processes, including innate immunity, antiviral defence, autophagy, transcriptional regulation, cell proliferation, differentiation and protein quality control. Their modular architecture and specialised C‑terminal domains give them remarkable versatility, allowing TRIM ligases to act as precise regulators of signalling pathways across many cellular contexts.
- All TRIM proteins share a conserved tripartite motif, which defines the family. This motif consists of an N‑terminal RING finger domain, one or two B‑box domains, and a coiled‑coil region. The RING domain provides catalytic E3 ligase activity by binding ubiquitin‑charged E2 enzymes and facilitating direct ubiquitin transfer to substrates. The B‑box domains contribute to structural stability and protein–protein interactions, while the coiled‑coil region enables homo‑ and hetero‑dimerisation, allowing TRIM proteins to form higher‑order assemblies. The C‑terminal region varies widely among TRIM family members and contains specialised domains—such as PRY/SPRY, PHD‑BRD, COS or NHL domains—that determine substrate specificity and functional diversity.
- One of the most prominent roles of TRIM proteins is in innate immunity and antiviral defence. Members such as TRIM25 activate antiviral signalling by ubiquitinating the RNA sensor RIG‑I, enabling robust interferon responses. TRIM21 acts as an intracellular antibody receptor, binding antibody‑coated pathogens and targeting them for proteasomal degradation. TRIM5α restricts retroviral infection by recognising viral capsids and promoting their degradation or autophagic clearance. These functions highlight the central role of TRIM proteins as molecular sentinels that detect and eliminate pathogens.
- Beyond immunity, TRIM proteins are deeply involved in autophagy and protein quality control. TRIM16, TRIM32 and TRIM50 participate in the clearance of misfolded proteins, helping maintain proteostasis. TRIM5α and TRIM21 also contribute to selective autophagy of viral components. Mutations in TRIM32 are associated with muscular dystrophy and neurodegenerative disorders, illustrating how defects in TRIM‑mediated protein quality control can lead to disease.
- Several TRIM proteins play important roles in cell proliferation, differentiation and cancer biology. TRIM19 (also known as PML) forms nuclear bodies involved in transcriptional regulation, DNA repair and tumour suppression. TRIM24, TRIM28 and TRIM33 regulate chromatin structure and transcriptional repression, influencing cell fate decisions and epigenetic programming. Some TRIM proteins act as tumour suppressors, while others promote oncogenic signalling depending on cellular context. Dysregulation of TRIM proteins has been linked to various cancers, autoimmune diseases, neurodevelopmental disorders and viral pathogenesis.
- Mechanistically, TRIM proteins often assemble K63‑linked ubiquitin chains, which serve as scaffolding signals rather than degradation tags. These chains modulate signalling pathways by recruiting downstream effectors or altering protein localisation. Some TRIM proteins also generate K48‑linked chains, targeting substrates for proteasomal degradation. Their ability to produce distinct ubiquitin chain types allows TRIM ligases to fine‑tune cellular responses with high precision.
- In summary, the TRIM family of ubiquitin ligases represents a versatile and evolutionarily conserved regulatory system that integrates ubiquitination, protein scaffolding and signalling modulation. Their tripartite motif provides a robust structural foundation, while diverse C‑terminal domains enable specialised functions across immunity, autophagy, development and cancer biology. As research continues to uncover new roles for TRIM proteins, they remain at the forefront of molecular biology and biomedical research, offering promising avenues for therapeutic intervention in infectious diseases, cancer and immune disorders.
